Drug Trial Radar · NCT06687174
Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)
Last checked: Nov 20, 2026Latest source record: Nov 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
72
Planned (sponsor's estimate)
Start
Dec 31, 2024
Primary completion
Jun 15, 2026
Study completion Jan 31, 2028
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Efficacy and safety of MY008211A in IgAN patients
Conditions
- IgA Nephropathy (IgAN)
Interventions
MY008211A tabletsDrug
MY008211A BID
MY008211A tablets matched placeboDrug
Matching placebo to MY008211A taken twice a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ratio of urine protein to creatinine concentration ratio (UPCR based on 24h urine collection, 24h-UPCR) relative to baseline at Week 12.Time frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.